94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Qiang Wang1,2
Yuemei Xi1,2Binyang Chen1,2Hairong Zhao1,2
Wei Yu1,2
De Xie1,2Weidong Liu1,2
Furong He1,2Chenxi Xu1,2
Jidong Cheng1,2*- 1Department of Internal Medicine, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
- 2Xiamen Key Laboratory of Translational Medicine for Nucleic Acid Metabolism and Regulation, Xiamen, China
by Wang Q, Xi Y, Chen B, Zhao H, Yu W, Xie D, Liu W, He F, Xu C and Cheng J (2022). Front. Pharmacol. 13:907133. doi: 10.3389/fphar.2022.907133
In the published article, there was an error in affiliation 1. Instead of “Department of Endocrinology, Xiang’an Hospital of Xiamen University, Xiamen, China”, it should be “Department of Internal Medicine, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China”.
In the published article, the reference Elimam et al. was not cited. The citation has now been inserted in Discussion, Paragraph 6, and now reads:
“Apart from being a source of energy, fatty acids are also engaged in the formation of mitochondrial membrane phospholipids. Calcium-independent Phospholipase A2γ can repair damaged mitochondrial membrane phospholipids by hydrolyzing damaged acyl chains to make them re-esterify with fatty acids and thus maintain mitochondrial survival and function, including FAO (Elimam et al., 2013).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Reference
Keywords: rage, cisplatin-induced nephrotoxicity, apoptosis, inflammation, fatty acid oxidation
Citation: Wang Q, Xi Y, Chen B, Zhao H, Yu W, Xie D, Liu W, He F, Xu C and Cheng J (2022) Corrigendum: Receptor of advanced glycation end products deficiency attenuates cisplatin-induced acute nephrotoxicity by inhibiting apoptosis, inflammation and restoring fatty acid oxidation. Front. Pharmacol. 13:1022539. doi: 10.3389/fphar.2022.1022539
Received: 18 August 2022; Accepted: 19 October 2022;
Published: 01 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Wang, Xi, Chen, Zhao, Yu, Xie, Liu, He, Xu and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jidong Cheng, amlkb25nY2hlbmczNkBob3RtYWlsLmNvbQ==